Updates are available Correction dated 2024-12-06

Article History

Accepted: 27 October 2024

First Online: 23 November 2024

Change Date: 5 December 2024

Change Type: Update

Change Details: The original version of this paper was updated to correct the citation of Table 1 in the first paragraph of section "Constitutional (Germline) Testing in Patients Diagnosed with Non‑Anaplastic Follicular Cell‑Derived Thyroid Cancer" to Table 2.

Change Date: 6 December 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12022-024-09843-y

Declarations

:

: Not applicable for this publication.

: All authors approved the final version and publication of the manuscript.

: All authors report honoraria (facilitated via Precision RxDx) from Eli Lilly Canada for participation in working group meetings related to this project.Dr. Ozgur Mete is the Editor-in-Chief of Endocrine Pathology. This article is handled by an independent senior editor as per Springer Nature’s policies. Dr. Mete received honorarium for serving as an advisory board member for Bayer.Dr. Andrée Boucher has received research support from Eisai and has been compensated for being a speaker and serving as a board member or on an advisory panel for Bayer and Eisai.Dr. Omar Abdel-Rahman has received consulting fees from Amgen, Eisai, Ipsen, Lilly, and Roche, honoraria from Bayer.Dr. Houda Bahig has received grants from AstraZeneca, Sanofi and Varian Medical Systems, as well as consulting fees from AstraZeneca and EMD Serono.Dr. Cheryl Ho received grants from AstraZeneca and Roche which were paid to her institution. She received honoraria for advisory board attendance from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, and Sanofi.Dr. Kasmintan A. Schrader has a consulting and advisory relationship with and has received honoraria from AstraZeneca Canada and Pfizer and research funding from AstraZeneca Canada and Merck.Dr. Eric Winquist received grants from Eli Lilly, Merck, and Novartis which were paid to his institution. He received consulting fees for advisory boards from Bayer, BMS, Eisai, EMD Serono, Merck, and Roche; honoraria from EMD Serono and support for attending meetings from Eisai.Dr. Jonn Wu served as an Executive board member, International Society of Oral Oncology, from 2019 to 2023.Dr. Shereen Ezzat has served as advisory board member/consultant for Bayer, Eisai, Eli Lilly, Ipsen, Novartis, Medunik Canada, Merck, Pfizer, and Recordati Rare Diseases.Dr. Nicole Chau has received research funding from BeiGene, BMS, ERASCA, Merck, and Roche which were paid to her institution. She received consulting fees for advisory boards from Bayer, BMS, Eisai, Eli Lilly, EMD Serono, Ipsen, Merck, Novartis, Pfizer, and Roche.Dr. Olfat Kamel Hasan, Dr. Bernard Lemieux, and Dr. Ralph Wong have no conflicts of interest to declare that are relevant to the content of this article.